BPGbio to Present Research and Pipeline Advancements on Mitochondrial Medicine at EBEC 2024
19 Agosto 2024 - 6:00AM
Business Wire
BPGbio joins leading mitochondrial researchers
at EBEC 2024, sponsoring student fellowships and presenting
groundbreaking advancements in AI-powered drug development
BPGbio, Inc., a leading biology-first, AI-powered, clinical
stage biopharma focused on mitochondrial biology and protein
homeostasis, today announced its sponsorship and participation in
the European Bioenergetics Conference (EBEC) 2024. The conference,
taking place August 26-31, 2024, in Innsbruck, Austria, is the
premier gathering for mitochondrial and bioenergetic translational
researchers worldwide.
BPGbio team plans to present the success of its proprietary
Interrogative Biology Platform, NAi, in advancing its
mitochondrial-biology focused clinical compound BPM31510, currently
in active phase 2 trials in aggressive cancers, and exploring phase
3 trials for Primary CoQ10 Deficiency and Primary Mitochondrial
Disease.
As part of its commitment to fostering innovation in science,
particularly in mitochondrial medicine, BPGbio is sponsoring a
registration fellowship for three outstanding graduate students at
the conference.
“As a key player in the mitochondrial medicine space, BPGbio is
honored and excited to be part of the EBEC conference to share with
fellow researchers and industry peers the progress we’ve made in
advancing our insights in mitochondrial biology that have led to
our BPM 31510 franchise,” said Niven R. Narain, Ph.D., President
and CEO of BPGbio. “I’d like to extend my congratulations to the
remarkable students who have won BPGbio award sponsorship at this
event with their outstanding research. We look forward to seeing
their contributions to the field helping to address the unmet need
for treatments to diseases that are mitochondrially based."
BPGbio Presentation
On August 27th, 2024 at 2:40 p.m., BPGbio will host a 20-minute
presentation entitled, “The 6 B’s of CoQ10 Therapeutic Development:
BPM31510, Bioenergetics, Biophysics, Bench, Bedside, and Back
Again,” featuring BPGbio executives Niven Narain, Ph.D.; Michael A.
Kiebish, Ph.D., VP of Platform and Translational Sciences; and
Vijay Modur, M.D., Ph.D., Chief Medical Officer. The BPGbio team
will discuss the biochemical, biophysical, and translational
clinical effects of BPM31510 on oncology and metabolic diseases,
showcasing BPGbio's pioneering advancements and the impactful role
of AI in drug development. Also, BPGbio will be presenting the
student registration fellowship awards to the recipients on August
30th during the meeting.
Student Award Sponsorship
BPGbio is sponsoring full registration for the conference for
the following students based on their exceptional abstracts:
- Federica Boscolo Nata, University of Padua, IT
- Carmen Morales Vidal, Spanish National Center for
Cardiovascular Research, ES
- Tijn van der Velden, Leiden University, NL
BPM31510 for Mitochondrial Diseases
Derived by the NAi Interrogative Platform, BPM31510(IV) is a
novel, highly bioavailable, CoQ10 metabolic approach to therapy. In
clinical trials, BPM31510 has demonstrated the benefit of
increasing levels of CoQ10 in cancer cells, restoring the normal
process of energy generation in the mitochondria leading to tumor
cell death. This revolutionary lipid conjugate molecule addresses
CoQ10 bioavailability issues in many mitochondrial diseases by
restoring CoQ10 levels to overcome the effect of mutations in genes
that lead to mitochondrial dysfunction. This restoration of energy
generation can minimize tissue damage from toxic metabolites and
preserve function in organs, such as the brain and heart.
About BPGbio Inc.
BPGbio is a leading biology-first AI-powered clinical stage
biopharma focused on mitochondrial biology and protein homeostasis.
The company has a deep pipeline of AI-developed therapeutics
spanning oncology, rare disease and neurology, including several in
late-stage clinical trials. BPGbio’s novel approach is underpinned
by NAi, its proprietary Interrogative Biology Platform, protected
by over 400 US and international patents; one of the world’s
largest clinically annotated non-governmental biobanks with
longitudinal samples; and exclusive access to the most powerful
supercomputer in the world. With these tools, BPGbio is redefining
how patient biology can be modeled using bespoke Bayesian AI
specifically designed for solving large-scale biology challenges.
Headquartered in greater Boston, the company is at the forefront of
a new era in medicine, combining biology, multi-modal data, and AI
to transform the way we understand, diagnose, and treat disease.
For more information, visit www.bpgbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819587079/en/
media@bpgbio.com